Latest Commercial Development News

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

Macallum New Energy has successfully listed on the ASX and raised A$7.4 million to fund exploration in the Northern Perth Basin. The company is progressing a 66% complete Barberton 3D seismic survey and preparing a Condor 2D survey, positioning itself amid renewed regional drilling activity.

Terramin Australia has advanced its flagship Tala Hamza Zinc Project into early development with strong Algerian government backing and a revised 2.0Mtpa mining study. Meanwhile, a court ruling returned the Bird in Hand Gold deposit to the company, prompting strategic reviews, all while the group manages a tight cash position supported by a recent $1 million share placement.

Invictus Energy has raised $10 million in a placement to fund the drilling of the Musuma-1 exploration well, targeting a substantial gas and condensate resource in Zimbabwe’s Cabora Bassa Basin. The well, planned for H2 2026, aims to build on the Mukuyu discovery and accelerate commercial development.

Amplitude Energy lifted gas prices and revenue to new quarterly highs in Q3 FY26 while pushing ahead with the East Coast Supply Project, despite mixed exploration results. The company’s production remains robust with capacity expansions at Orbost and development drilling in Cooper and Otway basins.

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.

Buru Energy has secured $5.3 million through a two-tranche placement to fund enhanced development of the Rafael Gas Project, following a significant uplift in project economics from new engineering insights.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Metallium Limited has completed Phase I of a U.S. Department of War SBIR contract, demonstrating its Flash Joule Heating technology can recover gallium from semiconductor and electronic waste. The program finished in six months, underscoring the technology’s readiness and aligning with U.S. strategic supply chain goals.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.

Everest Metals Corporation has reported promising metallurgical test results for its Mt Edon Critical Mineral Project, alongside submitting a key Mining Proposal to regulators, signalling progress toward commercial development.